AHMEMZO
LIVE

Serial Number

98247807

Owner

BRISTOL-MYERS SQUIBB COMPANY

Attorney

Xiomara Triana

Filing Date

Oct 31, 2023

Add to watchlist:

No watchlists yet
View on USPTO

AHMEMZO Trademark

Serial Number: 98247807

AHMEMZO is a trademark filed by BRISTOL-MYERS SQUIBB COMPANY on October 31, 2023. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

BRISTOL-MYERS SQUIBB COMPANY (4,799 trademarks)

NEW YORK, NY 10154

Entity Type: 03

Trademark Details

Filing Date

October 31, 2023

Registration Date

Not Registered

Published for Opposition

May 13, 2025

Goods & Services

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T-Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical and clinical use; Pharmaceutical preparations for human use for the treatment and prevention of COVID-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment and prevention of COVID-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use; Pharmaceutical preparations for human use for the treatment of neuropsychiatric disorders; therapeutic radiopharmaceutical preparations for human use for the treatment of cancer and solid tumors; diagnostic radiopharmaceutical preparations for human use; diagnostic agents, preparations and substances for medical purposes for human use; radiopharmaceutical imaging and detection agents for diagnosing and monitoring cancer for human use; pharmaceutical preparations for human use in the nature of radio-isotope markers for therapeutic and diagnostic use.

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 13, 2025 EXRA
SOU EXTENSION 1 GRANTED
Dec 12, 2025 EX1G
SOU EXTENSION 1 FILED
Dec 12, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Dec 12, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jul 8, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 13, 2025 NPUB
PUBLISHED FOR OPPOSITION
May 13, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 7, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 10, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 10, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 10, 2025 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Mar 10, 2025 ERFR
NOTIFICATION OF SUBSEQUENT FINAL EMAILED
Feb 13, 2025 GNS1
CONTINUATION OF FINAL REFUSAL E-MAILED
Feb 13, 2025 GNCF
ACTION CONTINUING A FINAL - COMPLETED
Feb 13, 2025 CNCF
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 9, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 9, 2025 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Jan 9, 2025 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Oct 9, 2024 GNFN
FINAL REFUSAL E-MAILED
Oct 9, 2024 GNFR
FINAL REFUSAL WRITTEN
Oct 9, 2024 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 11, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 11, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 11, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 14, 2024 GNRN
NON-FINAL ACTION E-MAILED
Jun 14, 2024 GNRT
NON-FINAL ACTION WRITTEN
Jun 14, 2024 CNRT
ASSIGNED TO EXAMINER
Jun 10, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 9, 2023 NWOS
NEW APPLICATION ENTERED
Nov 3, 2023 NWAP